Silexion closes $2.5M public offering; converts $750K debt to equity

Silexion Therapeutics Corp

Offered 2,028,619 shares, 1,817,542 pre-funded warrants, 3,846,161 Series E warrants at $0.65/unit; gross proceeds ~$2.5M.
Net proceeds ~$2.1M; intended for SIL204 clinical trial and general corporate purposes.
Converted $750,001 of sponsor note into 1,153,848 ordinary shares at $0.65/share; note balance now $206,462.
Issued 823,770 shares from pre-funded warrant exercises; adjusted shareholders' equity ~$3.2M as of June 30, 2026.
H.C. Wainwright sole placement agent; fees 7% cash, 1% management, plus 269,231 placement agent warrants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.